메뉴 건너뛰기




Volumn 29, Issue 2, 2013, Pages 242-249

High rate of antiretroviral drug resistance mutations in HIV type 1-infected senegalese children in virological failure on first-line treatment according to the world health organization guidelines

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE; PROTEINASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRANSCRIPTASE; VIRUS RNA;

EID: 84872943478     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0300     Document Type: Article
Times cited : (31)

References (51)
  • 1
    • 79551672781 scopus 로고    scopus 로고
    • rfaut Joint United Nations Joint United Nations Programme on HIV/AIDS. Accessed May 2011. Available from
    • Joint United Nations Programme on HIV/AIDS: Report on the Global AIDS Epidemic. Joint United Nations Programme on HIV/AIDS 2010. Accessed May 2011. Available from http://www.unaids.org/en/media/unaids/contentassets/documents/ unaidspublication/2010/20101123-globalreport- en.pdf.
    • (2010) Programme on HIV/AIDS: Report on the Global AIDS Epidemic.
  • 2
    • 33748125153 scopus 로고    scopus 로고
    • Survival rate and risk factors of mortality among HIV/tuberculosis- coinfected patients with and without antiretroviral therapy
    • DOI 10.1097/01.qai.0000230521.86964.86, PII 0012633420060900000007
    • Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, and Sungkanuparph S: Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006;43:42-46. (Pubitemid 44306486)
    • (2006) Journal of Acquired Immune Deficiency Syndromes , vol.43 , Issue.1 , pp. 42-46
    • Manosuthi, W.1    Chottanapand, S.2    Thongyen, S.3    Chaovavanich, A.4    Sungkanuparph, S.5
  • 5
    • 80053220672 scopus 로고    scopus 로고
    • HIV-1-resistance-associated mutations after failure of firstline antiretroviral treatment among children in resourcepoor regions: A systematic review
    • Sigaloff KC, Calis JC, Geelen SP, van Vugt M, and De Wit TF: HIV-1-resistance-associated mutations after failure of firstline antiretroviral treatment among children in resourcepoor regions: A systematic review. Lancet Infect Dis 2011; 11:769-779.
    • (2011) Lancet Infect Dis , vol.11 , pp. 769-779
    • Sigaloff, K.C.1    Calis, J.C.2    Geelen, S.P.3    Van Vugt, M.4    De Wit, T.F.5
  • 9
    • 48749107884 scopus 로고    scopus 로고
    • Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan
    • Adjé-Touré C, Hanson DL, Talla-Nzussouo N, et al.: Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Cô te d'Ivoire. AIDS Res Hum Retroviruses 2008;24:911-917.
    • (2008) Cô te d'Ivoire. AIDS Res Hum Retroviruses , vol.24 , pp. 911-917
    • Adjé-Touré, C.1    Hanson, D.L.2    Talla-Nzussouo, N.3
  • 10
    • 62749141273 scopus 로고    scopus 로고
    • High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations
    • Gody JC, Charpentier C, Mbitikon O, et al.: High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. J Acquir Immune Defic Syndr 2008;49:566-569.
    • (2008) J Acquir Immune Defic Syndr , vol.49 , pp. 566-569
    • Gody, J.C.1    Charpentier, C.2    Mbitikon, O.3
  • 11
    • 74049104390 scopus 로고    scopus 로고
    • Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure
    • Vaz P, Chaix ML, Jani I, et al.: Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure. Pediatr Infect Dis J 2009;28:e283-287.
    • (2009) Pediatr Infect Dis J , vol.28
    • Vaz, P.1    Chaix, M.L.2    Jani, I.3
  • 12
    • 77950353556 scopus 로고    scopus 로고
    • Level of viral load and antiretroviral resistance after 6 months of nonnucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali
    • Germanaud D, Derache A, Traore M, et al.: Level of viral load and antiretroviral resistance after 6 months of nonnucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. J Antimicrob Chemother 2010;65:118-124.
    • (2010) J Antimicrob Chemother , vol.65 , pp. 118-124
    • Germanaud, D.1    Derache, A.2    Traore, M.3
  • 13
    • 78650714700 scopus 로고    scopus 로고
    • Early failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children
    • Ruel TD, Kamya MR, Li P, et al.: Early failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr 2011;56:44-50.
    • (2011) J Acquir Immune Defic Syndr , vol.56 , pp. 44-50
    • Ruel, T.D.1    Kamya, M.R.2    Li, P.3
  • 14
    • 84855594339 scopus 로고    scopus 로고
    • Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A crosssectional evaluation in HIV type 1-infected children living in Central African Republic
    • Charpentier C, Gody JC, Mbitikon O, et al.: Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A crosssectional evaluation in HIV type 1-infected children living in Central African Republic. AIDS Res Hum Retroviruses 2012;28:87-94.
    • (2012) AIDS Res Hum Retroviruses , vol.28 , pp. 87-94
    • Charpentier, C.1    Gody, J.C.2    Mbitikon, O.3
  • 17
    • 47649104656 scopus 로고    scopus 로고
    • Antiretroviral therapy for HIV infection in infants and children: Toward universal access
    • World Health Organization. Geneva. World Health Organization. Accessed January 2010. Available from
    • World Health Organization: Antiretroviral therapy for HIV infection in infants and children: Toward universal access. Recommendations for a public health approach. Geneva. World Health Organization 2007. Accessed January 2010. Available from http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf.
    • (2007) Recommendations for a public health approach
  • 21
    • 47649104656 scopus 로고    scopus 로고
    • Antiretroviral therapy for HIV infection in infants and children: Towards universal access
    • World Health Organization. World Health Organization. Accessed July 2011. Available from
    • World Health Organization: Antiretroviral therapy for HIV infection in infants and children: Towards universal access. Recommendations for a public health approach. World Health Organization 2010. Accessed July 2011. Available from http://whqlibdoc.who.int/publications/2010/9789241599801-eng.pdf.
    • (2010) Recommendations for a public health approach
  • 23
    • 34147098059 scopus 로고    scopus 로고
    • Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from Kwazulu-Natal, South Africa
    • Reddi A, Leeper SC, Grobler AC, et al.: Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from Kwazulu-Natal, South Africa. BMC Pediatr 2007;17:7-13.
    • (2007) BMC Pediatr , vol.17 , pp. 7-13
    • Reddi, A.1    Leeper, S.C.2    Grobler, A.C.3
  • 24
    • 70249136191 scopus 로고    scopus 로고
    • Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy
    • Jittamala P, Puthanakit T, Chaiinseeard S, and Sirisanthana V: Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J 2009;28:826-830.
    • (2009) Pediatr Infect Dis J , vol.28 , pp. 826-830
    • Jittamala, P.1    Puthanakit, T.2    Chaiinseeard, S.3    Sirisanthana, V.4
  • 25
    • 36048946593 scopus 로고    scopus 로고
    • Effectiveness of highly active antiretroviral therapy in HIV-positive children: Evaluation at 12 months in a routine program in Cambodia
    • DOI 10.1542/peds.2006-3503
    • Janssens B, Raleigh B, Soeung S, et al.: Effectiveness of highly active antiretroviral therapy in HIV-positive children: Evaluation at 12 months in a routine program in Cambodia. Pediatrics 2007;120:e1134-1140. (Pubitemid 350085507)
    • (2007) Pediatrics , vol.120 , Issue.5
    • Janssens, B.1    Raleigh, B.2    Soeung, S.3    Akaob, K.4    Te, V.5    Gupta, J.6    Vun, M.C.7    Ford, N.8    Nouhinf, J.9    Nerrienet, E.10
  • 26
    • 0036488217 scopus 로고    scopus 로고
    • Efficacy of highly active antiretroviral therapy in HIV-1 infected children
    • DOI 10.1016/S1473-3099(02)00183-4
    • van Rossum AM, Fraaij PL, and De Groot R: Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002;2:93-102. (Pubitemid 36114143)
    • (2002) Lancet Infectious Diseases , vol.2 , Issue.2 , pp. 93-102
    • Van Rossum, A.M.C.1    Fraaij, P.L.A.2    De Groot, R.3
  • 27
    • 74049138608 scopus 로고    scopus 로고
    • Emergence of drug resistance in HIV-1 subtype C infected children failing the South African national antiretroviral roll-out program
    • Wallis CL, Erasmus L, Varughese S, Ndiweni D, and Stevens WS: Emergence of drug resistance in HIV-1 subtype C infected children failing the South African national antiretroviral roll-out program. Pediatr Infect Dis J 2009;28: 1123-1125.
    • (2009) Pediatr Infect Dis J , vol.28 , pp. 1123-1125
    • Wallis, C.L.1    Erasmus, L.2    Varughese, S.3    Ndiweni, D.4    Stevens, W.S.5
  • 28
    • 77952556299 scopus 로고    scopus 로고
    • Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda
    • Towler WI, Barlow-Mosha L, Church JD, et al.: Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. AIDS Res Hum Retroviruses 2010;26:563-568.
    • (2010) AIDS Res Hum Retroviruses , vol.26 , pp. 563-568
    • Towler, W.I.1    Barlow-Mosha, L.2    Church, J.D.3
  • 29
    • 33847369795 scopus 로고    scopus 로고
    • La résistance du VIH-1 aux antirétroviraux chez les enfants infectés: du nouveau-né a l'adolescent
    • DOI 10.1016/j.arcped.2006.12.007, PII S0929693X06006269
    • Delaugerre C, Chaix M L, Warszawki J, Rouzioux C, and Blanche S: HIV-1 drug resistance in French infectedchildren: From newborn to adolescent. Arch Pediatr 2007;14: 298-302. (Pubitemid 46349610)
    • (2007) Archives De Pediatrie , vol.14 , Issue.3 , pp. 298-302
    • Delaugerre, C.1    Chaix, M.-L.2    Warszawski, J.3    Rouzioux, C.4    Blanche, S.5
  • 30
    • 70249136191 scopus 로고    scopus 로고
    • Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy
    • Podjanee J, Thanyawee P, Sukrapee C, and Virat S: Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J 2009;28:826-830.
    • (2009) Pediatr Infect Dis J , vol.28 , pp. 826-830
    • Podjanee, J.1    Thanyawee, P.2    Sukrapee, C.3    Virat, S.4
  • 31
    • 1542618485 scopus 로고    scopus 로고
    • Comparison of Drug Resistance Mutations and Their Interpretation in Patients Infected with Non-B HIV-1 Variants and Matched Patients Infected with HIV-1 Subtype B
    • DOI 10.1097/00126334-200404010-00001
    • Montes B, Vergne L, Peeters M, Reynes J, Delaporte E, and Segondy M: Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J Acquir Immune Defic Syndr 2004;35:329-336. (Pubitemid 38332792)
    • (2004) Journal of Acquired Immune Deficiency Syndromes , vol.35 , Issue.4 , pp. 329-336
    • Montes, B.1    Vergne, L.2    Peeters, M.3    Reynes, J.4    Delaporte, E.5    Segondy, M.6
  • 32
    • 0029024089 scopus 로고
    • Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)
    • Schuurman R, Nijhuis M, van Leeuwen R, et al.: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171: 1411-1419.
    • (1995) J Infect Dis , vol.171 , pp. 1411-1419
    • Schuurman, R.1    Nijhuis, M.2    Van Leeuwen, R.3
  • 34
    • 11844278253 scopus 로고    scopus 로고
    • Rationale for maintenance of the M184V resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients
    • Turner D, Brenner BG, Routy JP, Petrella M, and Wainberg MA: Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol 2004;27:31-39. (Pubitemid 40090987)
    • (2004) New Microbiologica , vol.27 , Issue.2 SUPPL. 1 , pp. 31-39
    • Turner, D.1    Brenner, B.G.2    Routy, J.-P.3    Petrella, M.4    Wainberg, M.A.5
  • 35
    • 59649126954 scopus 로고    scopus 로고
    • In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine
    • Paredes R, Sagar M, Marconi VC, et al.: In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol 2009;83:2038-2043.
    • (2009) J Virol , vol.83 , pp. 2038-2043
    • Paredes, R.1    Sagar, M.2    Marconi, V.C.3
  • 37
    • 0037118912 scopus 로고    scopus 로고
    • M184V is associated with a iow incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine
    • DOI 10.1097/00002030-200208160-00017
    • Ait-Khaled M, Stone C, Amphlett G, et al.: M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 2002;16:1686-1689. (Pubitemid 34921117)
    • (2002) AIDS , vol.16 , Issue.12 , pp. 1686-1689
    • Ait-Khaled, M.1    Stone, C.2    Amphlett, G.3    Clotet, B.4    Staszewski, S.5    Katlama, C.6    Tisdale, M.7
  • 38
    • 0038369071 scopus 로고    scopus 로고
    • HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study
    • Ait-Khaled M, Rakik A, Griffin P, et al.: HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CAN 2007 study. Antivir Ther 2003;8: 111-120. (Pubitemid 36565891)
    • (2003) Antiviral Therapy , vol.8 , Issue.2 , pp. 111-120
    • Ait-Khaled, M.1    Rakik, A.2    Griffin, P.3    Stone, C.4    Richards, N.5    Thomas, D.6    Falloon, J.7    Tisdale, M.8
  • 39
    • 0036124432 scopus 로고    scopus 로고
    • The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1
    • DOI 10.1128/JVI.76.7.3248-3256.2002
    • Boyer PL, Sarafianos SG, Arnold E, and Hughes SH: The M184V mutation reduces the selective excision of zidovudine 5¢-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J Virol 2002;76:3248-3256. (Pubitemid 34224526)
    • (2002) Journal of Virology , vol.76 , Issue.7 , pp. 3248-3256
    • Boyer, P.L.1    Sarafianos, S.G.2    Arnold, E.3    Hughes, S.H.4
  • 44
    • 79955450369 scopus 로고    scopus 로고
    • Excellent adherence to antiretrovirals in HIV + Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects
    • Haberer JE, Cook A, Walker AS, et al.: Excellent adherence to antiretrovirals in HIV + Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects. PLoS One 2011;6:e18505.
    • (2011) PLoS One , vol.6
    • Haberer, J.E.1    Cook, A.2    Walker, A.S.3
  • 45
    • 77950263958 scopus 로고    scopus 로고
    • Surveillance of transmitted resistance to antiretroviral drug classes among young children in the Western Cape Province of South Africa
    • vanZyl GU, CottonMF, ClaassenM, Abrahams C, and Preiser W: Surveillance of transmitted resistance to antiretroviral drug classes among young children in the Western Cape Province of South Africa. Pediatr Infect Dis J 2010;29:370-371.
    • (2010) Pediatr Infect Dis J , vol.29 , pp. 370-371
    • Van Zyl, G.U.1    Cotton, M.F.2    Claassen, M.3    Abrahams, C.4    Preiser, W.5
  • 46
    • 83455200006 scopus 로고    scopus 로고
    • Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic
    • Charpentier C, Gody JC, Tisserand P, et al.: Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic. Antiviral Ther 2011;16:1347-1350.
    • (2011) Antiviral Ther , vol.16 , pp. 1347-1350
    • Charpentier, C.1    Gody, J.C.2    Tisserand, P.3
  • 47
    • 79951715989 scopus 로고    scopus 로고
    • Virological failure and HIV type 1 drug resistance profiles among patients followed-up in private sector, Douala, Cameroon
    • Charpentier C, Talla F, Nguepi E, Si-Mohamed A, and Be'lec L: Virological failure and HIV type 1 drug resistance profiles among patients followed-up in private sector, Douala, Cameroon. AIDS Res Hum Retroviruses 2011;27:221-230.
    • (2011) AIDS Res Hum Retroviruses , vol.27 , pp. 221-230
    • Charpentier, C.1    Talla, F.2    Nguepi, E.3    Si-Mohamed, A.4    Be'lec, L.5
  • 48
    • 77957135518 scopus 로고    scopus 로고
    • Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children
    • Buck WC, Kabue MM, Kazembe PN, and Kline MW: Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children. J Int AIDS Soc 2010;13:31.
    • (2010) J Int AIDS Soc , vol.13 , pp. 31
    • Buck, W.C.1    Kabue, M.M.2    Kazembe, P.N.3    Kline, M.W.4
  • 49
    • 62849127651 scopus 로고    scopus 로고
    • Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms
    • Cotte L, Trabaud MA, Tardy JC, et al.: Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms. J Med Virol 2009; 81:672-677.
    • (2009) J Med Virol , vol.81 , pp. 672-677
    • Cotte, L.1    Trabaud, M.A.2    Tardy, J.C.3
  • 50
    • 70449601946 scopus 로고    scopus 로고
    • Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: The Swiss HIV Cohort Study (SHCS)
    • Scherrer AU, Hasse B, von Wyl V, et al.: Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: The Swiss HIV Cohort Study (SHCS). HIV Med 2009;10:647-656.
    • (2009) HIV Med , vol.10 , pp. 647-656
    • Scherrer, A.U.1    Hasse, B.2    Von Wyl, V.3
  • 51
    • 75749098448 scopus 로고    scopus 로고
    • Resistanceassociated mutations to etravirine (TMC-125) in antiretroviral-nai?ve patients infected with non-B HIV-1 subtypes
    • Mai?ga AI, Descamps D, Morand-Joubert L, et al.: Resistanceassociated mutations to etravirine (TMC-125) in antiretroviral-nai?ve patients infected with non-B HIV-1 subtypes. Antimicrob Agents Chemother 2010;54:728-733.
    • (2010) Antimicrob Agents Chemother , vol.54 , pp. 728-733
    • Maiga, A.I.1    Descamps, D.2    Morand-Joubert, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.